5% Imiquimod Cream for the Treatment of Cutaneous Tumor / 대한피부과학회지

ABSTRACT

BACKGROUND: Imiquimod is an immune response modifier that shows antiproliferative and antiviral characteristics through synthesis of multiple cytokines. Although it was originally approved by the FDA for the treatment of genital warts, it has also been successfully used to treat various dermatological conditions. OBJECTIVE: The aim of this study was to report our treatment experience of cutaneous tumors with 5% imiquimod cream, and to contemplate the effectiveness and safety of its use for purpose. METHODS: We reviewed 21 patients with biopsy-proven cutaneous tumors who were treated with 5% imiquimod cream. Data was collected through medical records, clinical photographs, and biopsy specimens. RESULTS: The patients had various cutaneous tumors including actinic keratosis, Bowen's disease, Bowenoid papulosis, keratoacanthoma, superficial basal cell carcinoma and invasive squamous cell carcinoma. Among 17 patients who were initially treated with 5% imiquimod cream, 13 patients (76.5%) achieved clinical complete remission, and histologic cure was also confirmed in four. No recurrence was observed during the follow up period in these 13 patients. While applying 5% imiquimod cream, all the patients experienced local side effects but it was mild and generally well-tolerated. CONCLUSION: Topical immunotherapy of cutaneous tumors with 5% imiquimod cream has potential as a patient- friendly, well-tolerated therapy that can achieve cosmetically and functionally pleasing treatment outcomes.